USP: Over the past few decades, the supply chain for pharmaceuticals and their ingredients has expanded around the world, and so has the presence of substandard and counterfeit products. Notable adverse events related to poor quality medicines (e.g., heparin and glycerin contamination) have brought increased attention from policymakers, regulators, manufacturers, and consumers to the threat of using poor quality medicines.
INFORMATIONAL MATERIALS
The WHO Member State Mechanism 2022-2023
Access to safe, effective, and quality medical products is essential for universal health coverage. However, substandard and falsified medical products are frequently introduced into the global supply chain, leading to adverse health effects and socioeconomic Read more…